These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34859955)

  • 1. A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
    McKenzie A; Roberts A; Malandkar S; Feuersenger H; Panousis C; Pawaskar D
    Clin Transl Sci; 2022 Mar; 15(3):626-637. PubMed ID: 34859955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
    Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
    Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19.
    Papi A; Stapleton RD; Shore PM; Bica MA; Chen Y; Larbig M; Welte T
    Lung; 2023 Apr; 201(2):159-170. PubMed ID: 37000214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).
    Pawaskar D; Chen X; Glassman F; May F; Roberts A; Biondo M; McKenzie A; Nolte MW; Jusko WJ; Tortorici M
    Clin Transl Sci; 2022 Mar; 15(3):709-720. PubMed ID: 34811931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
    Craig TJ; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Alexandru Bica M; Jacobs I; Pragst I; Magerl M
    Lancet Haematol; 2024 Jun; 11(6):e436-e447. PubMed ID: 38710185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for the inhibition of βFXIIa by garadacimab.
    Drulyte I; Ghai R; Ow SY; Kapp EA; Quek AJ; Panousis C; Wilson MJ; Nash AD; Pelzing M
    Structure; 2024 Oct; 32(10):1705-1710.e3. PubMed ID: 39059382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting factor XIIa for therapeutic interference with hereditary angioedema.
    Cohn DM; Renné T
    J Intern Med; 2024 Oct; 296(4):311-326. PubMed ID: 39331688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
    Reshef A; Hsu C; Katelaris CH; Li PH; Magerl M; Yamagami K; Guilarte M; Keith PK; Bernstein JA; Lawo JP; Shetty H; Pollen M; Wieman L; Craig TJ;
    Allergy; 2024 Oct; ():. PubMed ID: 39370961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study investigating DX-2930 in healthy subjects.
    Chyung Y; Vince B; Iarrobino R; Sexton D; Kenniston J; Faucette R; TenHoor C; Stolz LE; Stevens C; Biedenkapp J; Adelman B
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):460-6.e2. PubMed ID: 24980392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor XII/XIIa inhibitors: Their discovery, development, and potential indications.
    Davoine C; Bouckaert C; Fillet M; Pochet L
    Eur J Med Chem; 2020 Dec; 208():112753. PubMed ID: 32883641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
    Nowotny B; Thomas D; Schwers S; Wiegmann S; Prange W; Yassen A; Boxnick S
    J Thromb Haemost; 2022 Jul; 20(7):1684-1695. PubMed ID: 35490404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure.
    Ward CL; Jamieson V; Nabata T; Sharpe J; Dozono K; Suto F; Hashimoto Y; Gussak I
    Clin Ther; 2016 May; 38(5):1109-21. PubMed ID: 27001444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.
    Samant M; Ziemniak J; Paolini JF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):306-314. PubMed ID: 37699709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.